These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29264517)

  • 1. Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
    Paepegaey AC; Lheure C; Ratour C; Lethielleux G; Clerc J; Bertherat J; Kramkimel N; Groussin L
    J Endocr Soc; 2017 Jun; 1(6):646-649. PubMed ID: 29264517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report.
    Khatri S; Alom M; Kashfi S; Atallah J; Goswami G
    J Investig Med High Impact Case Rep; 2023; 11():23247096231194401. PubMed ID: 37642143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
    Hakami OA; Ioana J; Ahmad S; Tun TK; Sreenan S; McDermott JH
    Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30836329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient.
    Spagnolo CC; Campo I; Campennì A; Cardile D; Cannavò S; Silvestris N; Santarpia M; Ruggeri RM
    Hormones (Athens); 2024 Dec; 23(4):759-764. PubMed ID: 38421588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
    de Filette J; Jansen Y; Schreuer M; Everaert H; Velkeniers B; Neyns B; Bravenboer B
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4431-4439. PubMed ID: 27571185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When Hormones are Being Difficult: A Rare Case and the Literature Review of Pembrolizumab-Induced Polyendocrinopathy.
    Tayyeb M; Tariq M; Khan AM; Khalid F; Meghal T; Du D
    J Community Hosp Intern Med Perspect; 2023; 13(6):90-94. PubMed ID: 38596553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Endocrine-Related Effects of Pembrolizumab Precipitating Severe Hyponatremia.
    Baldawi MB; Dhami B; Gosai J; Al-Khafaji RH
    Cureus; 2022 Aug; 14(8):e28393. PubMed ID: 36171843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab-Induced Thyroiditis.
    Imblum BA; Baloch ZW; Fraker D; LiVolsi VA
    Endocr Pathol; 2019 Jun; 30(2):163-167. PubMed ID: 31111437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.
    Ariyasu H; Inaba H; Ota T; Yamaoka H; Furukawa Y; Iwakura H; Doi N; Yamamoto Y; Akamizu T
    In Vivo; 2018; 32(2):345-351. PubMed ID: 29475919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
    Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
    J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gallbladder With a Mass.
    Fernandes NL; Sodavarapu S; Nedopil S; Mohapatra N; Vyas D
    Cureus; 2020 Jun; 12(6):e8786. PubMed ID: 32724737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
    Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
    BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency.
    Sonehara K; Tateishi K; Hirabayashi T; Araki T; Ikuyama Y; Machida R; Hanaoka M
    Case Rep Oncol; 2021; 14(1):1-7. PubMed ID: 33613234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer.
    Cunha C; Silva E; Vieira AC; Saraiva C; Duarte S
    Endocrinol Diabetes Metab Case Rep; 2022 Feb; 2022():. PubMed ID: 35140188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenal Insufficiency and Thyrotoxicosis Following Combined Immune Checkpoint Inhibitor Use: A Case Report and Literature Review.
    Fukushima K; Kitayama S; Sazuka M; Kodera R; Oba K; Toyoshima K; Chiba Y; Yamamoto H; Araki A; Tamura Y
    Cureus; 2024 May; 16(5):e60850. PubMed ID: 38910605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
    Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
    J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
    Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
    BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.